Found 304 articles for: "biologics"
Biologic Use During Pregnancy and Breastfeeding in Dermatology: An Evidence-Based Review
November 2024 | Volume 23 | Issue 11 | Original Article | 1010 | Copyright © November 2024
Biologic medications have revolutionized the treatment of many dermatologic conditions. However, their use during pregnancy and breastfeeding is a subject of ongoing concern due to limited data o...
Read MoreA Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment
October 2024 | Volume 23 | Issue 10 | Original Article | 825 | Copyright © October 2024
The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus...
Read MoreOpt for Methotrexate Before Biologics in the Treatment of Recalcitrant Delayed-Onset Reactions to Dermal Fillers
October 2024 | Volume 23 | Issue 10 | Editorials | 907 | Copyright © October 2024
Assessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments
October 2024 | Volume 23 | Issue 10 | Original Article | 847 | Copyright © October 2024
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions, characterized by recurrent eczema with varying degrees of erythema, pruritus, xerosis, and pain. Although there a...
Read MoreThe ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors
October 2024 | Volume 23 | Issue 10 | Original Article | 852 | Copyright © October 2024
Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed wa...
Read MoreStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis
October 2024 | Volume 23 | Issue 10 | Features | 903 | Copyright © October 2024
From Research to Practice: The Latest Data on Evolving Treatments for Chronic Spontaneous Urticaria
September 2024 | Volume 23 | Issue 9 | Features | 795 | Copyright © September 2024
Chronic spontaneous urticaria (CSU) should be on every dermatology practitioner's radar. CSU is a skin disorder marked by wheals, angioedema, or both for more than 6 weeks. Patients with CSU expe...
Read MoreEffect of Topical Human Platelet Extract (HPE) for Facial Skin Rejuvenation: A Histological Study of Collagen and Elastin
September 2024 | Volume 23 | Issue 9 | Original Article | 735 | Copyright © September 2024
Background: Regenerative aesthetics has garnered significant attention. In this toolkit, exosomes are small extracellular vesicles derived from various sources such as platelets....
Read MoreINDIVIDUAL ARTICLE: NECOM 4: Algorithm Integrating Skincare for the Management of Immunotherapy-Related Cutaneous Adverse Events for Cancer Patients and Survivors
August 2024 | Volume 23 | Issue 8 | Supplement Individual Articles | 85411s3 | Copyright © August 2024
Background: In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhi...
Read MoreTildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness a...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MoreApplications of Bruton Tyrosine Kinase Inhibitors in Dermatology
August 2024 | Volume 23 | Issue 8 | Features | 697 | Copyright © August 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
August 2024 | Volume 23 | Issue 8 | Original Article | 619 | Copyright © August 2024
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outco...
Read MoreThe Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study
August 2024 | Volume 23 | Issue 8 | Editorials | e169 | Copyright © August 2024
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024
Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-...
Read MoreRapid Remission of Plaque Psoriasis With Bimekizumab Treatment
August 2024 | Volume 23 | Issue 8 | Features | 694 | Copyright © August 2024
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recentl...
Read MorePalmoplantar Pustulosis: Therapy Update
August 2024 | Volume 23 | Issue 8 | Original Article | 626 | Copyright © August 2024
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic ...
Read MoreTreatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients
June 2024 | Volume 23 | Issue 6 | Editorials | e144 | Copyright © June 2024
Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. W...
Read MoreEfficacy and Safety of Micronized Isotretinoin Administered Once Daily Without Food in Patients With Recalcitrant Nodular Acne
June 2024 | Volume 23 | Issue 6 | Original Article | 423 | Copyright © June 2024
Introduction: Micronized isotretinoin 0.4 to 0.8 mg/kg/day administered in 2 divided doses with or without meals is approved for the treatment of severe nodular acne in patients ...
Read MoreDermatologists' Perspectives on Biosimilars
April 2024 | Volume 23 | Issue 4 | Features | 277 | Copyright © April 2024
Media and other results for: "biologics"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
